CCP
PNT

Clarkston Capital Partners’s POINT Biopharma Global Inc. Common Stock PNT Stock Holding History

Clarkston Capital Partners’s Portfolio PNT Stock Details PNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-22,545
Closed -$154K – 191
2022
Q2 		$154K Hold
22,545
– – ﹤0.01% 165
2022
Q1 		$180K Hold
22,545
– – ﹤0.01% 170
2021
Q4 		$126K Buy
+22,545
New +$169K ﹤0.01% 161

Other funds holding PNT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Clarkston Capital Partners's PNT Position: Q3 2022 in Review

Clarkston Capital Partners sold out of POINT Biopharma Global Inc. Common Stock (PNT) in Q3 2022, closing a stake of 22,545 shares — an estimated $154K sold.

Clarkston Capital Partners first reported a position in PNT in Q4 2021 and held it in 3 quarters. The position peaked at $180K in Q1 2022. 106 funds tracked by Wall St. Rank hold PNT as of Q3 2022.

  • Clarkston Capital Partners reported no remaining POINT Biopharma Global Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Clarkston Capital Partners sold 22,545 POINT Biopharma Global Inc. Common Stock shares in Q3 2022, an estimated $154K.
  • Clarkston Capital Partners first reported a position in POINT Biopharma Global Inc. Common Stock in Q4 2021 and held it in 3 quarters.
  • Clarkston Capital Partners's POINT Biopharma Global Inc. Common Stock position peaked at $180K in Q1 2022.
  • 106 funds tracked by Wall St. Rank held POINT Biopharma Global Inc. Common Stock as of Q3 2022.

Based on Clarkston Capital Partners's 13F filing for Q3 2022, filed 14 Nov 2022.